Kazia Therapeutics

Oncology-focused drug development company based in Sydney, Australia, developing brain-penetrant and targeted therapies for cancers with high unmet need; its lead asset paxalisib was licensed from Genentech in 2016 and has been studied in more than 15 clinical trials.

Company Info

Sector:Oncology

Headquarters:Sydney, New South Wales, Australia

Founded:1994

Website:www.kaziatherapeutics.com/

Upcoming Milestones & Key Dates

2027

Readout

Paxalisib Phase 1b/2a dose-expansion data in rare seizure disorders

Clinical Development Pipeline

paxalisib

Target: PI3K/Akt/mTOR pathway

Rare seizure disorders

Preclinical

Phase 1

Phase 2

Phase 3

Approved

paxalisib

Target: PI3K/Akt/mTOR pathway

Glioblastoma

Preclinical

Phase 1

Phase 2

Phase 3

Approved

EVT801

Target: VEGFR3

Advanced solid tumors

Preclinical

Phase 1

Phase 2

Phase 3

Approved

Leadership Team

John Friend II, MD

Chief Executive Officer

Sudha Rao, PhD

Chief Scientific Officer

Careers & Job Openings

See all open roles

All departments

Multiple locations

Apply Now →

Kazia Therapeutics

Company Info

Upcoming Milestones & Key Dates

Clinical Development Pipeline

paxalisib

paxalisib

EVT801

Recent News